Publications
701 results found
Mohamed Z, Kim JU, Magesa A, et al., 2019, High prevalence and poor linkage to care of transfusion transmitted infections among blood donors in Dar-es-Salaam, Tanzania, Journal of Viral Hepatitis, Vol: 26, Pages: 750-756, ISSN: 1352-0504
Blood transfusion is one of the most commonly relied upon therapies in sub‐Saharan Africa. Existing safeguards recommended include systematic screening for transfusion‐transmitted infections and restricted voluntary nonremunerated blood donor selection. We report the transfusion‐transmitted infection screening and notification practice at a large urban blood transfusion centre in Dar‐es‐Salaam, Tanzania. Between October 2016 and March 2017 anonymized records of all donors registered at the blood transfusion unit were accessed to retrospectively note demographic information, donor status, first‐time status, transfusion‐transmitted infection result and notification. 6402 consecutive donors were screened for transfusion‐transmitted infections; the majority were family/replacement blood donors (88.0%) and male (83.8%). Overall transfusion‐transmitted infections prevalence was 8.4% (95% CI 7.8‐9.1), with hepatitis B being the most prevalent infection (4.1% (95% CI 3.6‐4.6)). Transfusion‐transmitted infections were more common in family/replacement blood donors (9.0% (95% CI 8.3‐9.8)) as compared to voluntary nonremunerated blood donor (4.1% (95% CI 2.8‐5.7)). A minority of infected‐donors were notified of a positive result (8.5% (95% CI 6.3‐11.2)). Although transfusion‐transmitted infections are more prevalent among family/replacement blood donors, overall risk of transfusion‐transmitted infections across all groups is considerable. In addition, existing efforts to notify donors of a positive transfusion‐transmitted infection are poor. Future policies must focus on improving linkage to care for newly diagnosed patients with transfusion‐transmitted infections.
Bennett K, Enki D, Thursz M, et al., 2019, NON-SEVERE ALCOHOLIC HEPATITIS IS NOT A BENIGN CONDITION: SYSTEMATIC REVIEW AND META-ANALYSIS OF MORTALITY DATA, Annual Meeting of the British-Society-of-Gastroenterology (BSG), Publisher: BMJ PUBLISHING GROUP, Pages: A107-A107, ISSN: 0017-5749
Dusheiko G, Lemoine M, 2019, An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans., Journal of Hepatology, Vol: 70, Pages: 1046-1048, ISSN: 0168-8278
Yoshida K, Post G, Shimakawa Y, et al., 2019, Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe, JOURNAL OF HEPATOLOGY, Vol: 70, Pages: 1295-1297, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 7
Kaura A, Sterne J, Mulla A, et al., 2019, INVASIVE VERSUS MEDICAL MANAGEMENT OF ELDERLY PATIENTS WITH NON-ST ELEVATION MYOCARDIAL INFARCTION (NIHR HEALTH INFORMATICS COLLABORATIVE SENIOR-NSTEMI STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, Publisher: BMJ PUBLISHING GROUP, Pages: A48-A49, ISSN: 1355-6037
Cohen D, Shimakawa Y, Ndow G, et al., 2019, Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study, médecine/sciences, Vol: 35, Pages: 431-439, ISSN: 0767-0974
Despite the existence of an effective vaccine, HBV infects 257 million people worldwide and is the cause of the majority of HCC. With an annual mortality rate of 887 000 patients in 2015, this cancer is the second deadliest. Low-income countries such as ones in sub-Saharan Africa are the most at risk due to the limited access to healthcare. To overcome this and born from an international research collaboration within an EU project, the Prolifica study aimed at evaluating a screen-and-treat program to prevent HBV complications, and more particularly HCC. Based on communities, facilities and hospitals HBsAg+ detection, the study lasted from 2011 to 2016. From the “cost effectiveness” feasibility of such a program to the development of simple scores for antiviral treatment, Prolifica uncovered data of crucial importance in a region with low HBV infection awareness, transmissions modes and prevention means which could have impacts on public health policies.
Szabo G, Kamath PS, Shah VH, et al., 2019, Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study, HEPATOLOGY, Vol: 69, Pages: 2271-2283, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 51
Kaura A, Panoulas V, Glampson B, et al., 2019, THE RELATIONSHIP BETWEEN TROPONIN LEVEL AND MORTALITY IN AN UNSELECTED POPULATION OF OVER 250,000 PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME (NIHR HEALTH INFORMATICS COLLABORATIVE TROP-RISK STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, Publisher: BMJ PUBLISHING GROUP, Pages: A59-A59, ISSN: 1355-6037
Kaura A, Hartley A, Panoulas V, et al., 2019, THE ROLE OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PREDICTING MORTALITY BEYOND TROPONIN IN OVER 100,000 PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME (NIHR HEALTH INFORMATICS COLLABORATIVE CRP-RISK STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, Publisher: BMJ PUBLISHING GROUP, Pages: A120-A121, ISSN: 1355-6037
Kaura A, Arnold A, Panoulas V, et al., 2019, THE PROGNOSTIC IMPLICATION OF TROPONIN LEVEL IN OVER 3000 PATIENTS PRESENTING WITH ATRIAL FIBRILLATION (NIHR HEALTH INFORMATICS COLLABORATIVE AF-TROP STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, Publisher: BMJ PUBLISHING GROUP, Pages: A26-A27, ISSN: 1355-6037
Kaura A, Panoulas V, Glampson B, et al., 2019, THE PROGNOSTIC IMPLICATION OF A POSITIVE TROPONIN ACROSS THE AGE SPECTRUM IN A QUARTER OF A MILLION PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME (NIHR HEALTH INFORMATICS COLLABORATIVE TROP-RISK STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, Publisher: BMJ PUBLISHING GROUP, Pages: A121-A122, ISSN: 1355-6037
Ghani R, Gan C, Mullish B, et al., 2019, MP71-15 Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of Faecal Microbiota transplantation (FMT) as a treatment modality., AUA 2019, Publisher: Elsevier, ISSN: 0022-5347
Abeles RD, Mullish BH, Forlano R, et al., 2019, Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume, International Liver Congress, Publisher: ELSEVIER SCIENCE BV, Pages: E305-E305, ISSN: 0168-8278
Forlano R, Mullish BH, Giannakeas N, et al., 2019, SAT-294. Automated quantitation of steatosis, inflammation, ballooningand fibrosis using machine learning in routine histologicalimages of liver biopsies of patients with NAFLD, International Liver Congress (ILC), Publisher: Elsevier, Pages: e767-e768, ISSN: 0168-8278
Tyson LD, Atkinson S, Pechlivanis A, et al., 2019, Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis, International Liver Congress, Publisher: ELSEVIER SCIENCE BV, Pages: E108-E108, ISSN: 0168-8278
Maurice JB, Garvey L, Tsochatzis EA, et al., 2019, Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation., AIDS, Vol: 33, Pages: 805-814, ISSN: 0269-9370
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is common among people living with HIV. There are limited data available on the pathophysiology of NAFLD and the development of fibrosis in this population. OBJECTIVES: The aim of this study was to investigate the association of bacterial translocation, adipose tissue dysfunction, monocyte activation and gut dysbiosis in patients with HIV monoinfection and NAFLD. METHODS: Cases with biopsy-proven NAFLD and HIV monoinfection were age and sex-matched to HIV-positive and HIV-negative controls. Markers of bacterial translocation [lipopolysaccharide-binding protein (LBP), bacterial DNA and lipopolysaccharide (LPS)], adipose tissue dysfunction (leptin, adiponectin) and monocyte activation (sCD14 and sCD163) were measured by ELISA. Hepatic patterns of macrophage activation were explored with immunohistochemistry. 16 s rRNA sequencing was performed with stool. RESULTS: Thirty-three cases were included (≥F2 fibrosis n = 16), matched to HIV-positive (n = 29) and HIV-negative (n = 17) controls. Cases with NAFLD were more obese (BMI 31.0 ± 4.4 vs. 24.1 ± 2.8 kg/m, P < 0.001) and had significantly increased levels of sCD14, sCD163 and higher leptin to adiponectin ratio vs. HIV-positive controls. Cases with ≥F2 verses < F2 fibrosis had increased sCD14 (1.4 ± 0.4 vs. 1.1 ± 0.3 μg/ml, P = 0.023) and sCD163 (1.0 ± 0.3 vs. 0.8 ± 0.3 μg/ml, P = 0.060), which correlated with waist circumference (sCD14 P = 0.022, sCD163 P = 0.011). Immunohistochemistry showed increased hepatic portal macrophage clusters in patients with fibrosis. No markers of bacterial translocation or changes to the microbiome were associated with NAFLD or fibrosis. CONCLUSION: NAFLD fibrosis stage in HIV monoinfected patients is associated with monocyte activation in the context of obesity, which may be independent of bacterial translocation and gut microbiome.
Forlano R, Mullish BH, Yee M, et al., 2019, Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?, International Liver Congress, Publisher: ELSEVIER SCIENCE BV, Pages: E295-E295, ISSN: 0168-8278
Vergis N, Atkinson S, Thursz M, 2019, The future of therapy for alcoholic hepatitis - beyond corticosteroids, Journal of Hepatology, Vol: 70, Pages: 785-787, ISSN: 0168-8278
Corticosteroids are the only treatment proven to reduce mortality from severe alcoholic hepatitis (SAH), though the benefit is short-lived.1 Several potential therapies are currently under evaluation in human clinical trials (Table 1). These therapies target: i) malnutrition; ii) intestinal dysbiosis and its portal translocation; iii) bile acid production; iv) hepatocyte death; v) hepatocyte regeneration; and vi) life-threatening complications of the disease itself.
Mullish BH, Forlano R, Abeles RD, et al., 2019, Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic liver disease – authors’ reply, Alimentary Pharmacology and Therapeutics, Vol: 49, Pages: 1093-1094, ISSN: 0269-2813
Forrest E, Storey N, Sinha R, et al., 2019, A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E277-E278, ISSN: 0168-8278
Singanayagam A, Erminelli D, Triantafyllou E, et al., 2019, Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK plus immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E183-E183, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 1
Forrest E, Storey N, Sinha R, et al., 2019, Baseline neutrophil-to-lymphocyte ratio indicates both prevalent and incident infection and acute kidney injury, and is related to corticosteroid Lille response in alcoholic hepatitis, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E47-E47, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 1
Hamesch K, Atkinson S, Spivak I, et al., 2019, In severe alcoholic hepatitis, serum transferrin indicates impaired HNF4a signaling and predicts mortality independently of disease severity, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E278-E279, ISSN: 0168-8278
Triantafyllou E, Gudd C, Nathwani R, et al., 2019, PD-1+monocytes and macrophages contribute to impaired microbial clearance following acute liver failure, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E430-E431, ISSN: 0168-8278
Safinia N, Vaikunthanathan T, Trevelin SC, et al., 2019, A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E444-E444, ISSN: 0168-8278
Kumar N, Sadiq F, Mukherjee S, et al., 2019, The LLT1-CD161 interaction : An important inhibitory interaction for NK cells in cirrhosis, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E20-E21, ISSN: 0168-8278
Evans J, Pinato D, Ward C, et al., 2019, Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E362-E362, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 1
Khamri W, Gudd C, Krasniqi M, et al., 2019, Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-G+CD4+regulatory T -cell population, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E800-E800, ISSN: 0168-8278
Gudd CLC, Liu T, Triantafyllou E, et al., 2019, Elevated tissue homing of monocytes and increased cytotoxic activity of CD8+T-cells in immune checkpoint inhibitor-induced hepatitis, International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: E19-E20, ISSN: 0168-8278
Abeles RD, Mullish BH, Forlano R, et al., 2019, Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume, Alimentary Pharmacology and Therapeutics, Vol: 49, Pages: 1077-1085, ISSN: 0269-2813
Background: Atherosclerotic cardiovascular disease is a key cause of morbidity in non-alcoholic fatty liver disease (NAFLD) but appropriate means to predict major acute cardiovascular events (MACE) are lacking. Aims: To design a bespoke cardiovascular risk score in NAFLD. Methods: A retrospective derivation (2008-2016, 356 patients) and a prospective validation (2016- 2017, 111 patients) NAFLD cohort study was performed. Clinical and biochemical data were recorded at enrolment and mean platelet volume (MPV), Qrisk2 and Framingham scores were recorded one year prior to MACE (Cardiovascular death, acute coronary syndrome, stroke, and transient ischaemic attack). Results: The derivation and validation cohorts were well matched with MACE prevalence 12.6% and 12% respectively. On univariate analysis, age, diabetes, advanced fibrosis, collagen proportionate area >5%, MPV and liver stiffness were associated with MACE. After multivariate analysis, age, diabetes and MPV remained independently predictive. The ‘NAFLD CV-risk score’ was generated using binary logistic regression: 85860.06*(Age) + 0.963*(MPV) + 0.26*(DM1) – 16.441 Diabetes mellitus: 1: present; 2: absent. (AUROC 0.84). A cut-off of -3.98 gave a Sensitivity 97%, Specificity 27%, PPV 16%, NPV 99%. An MPV alone of >10.05 gave a sensitivity 97%, specificity 59%, PPV 24% and NPV 97% (AUROC 0.83). Validation cohort AUROCs were comparable at 0.77 (NAFLD CV-risk) and 0.72 (MPV). In the full cohort, the NAFLD CV-risk score and MPV outperformed both Qrisk2 and Framingham scores. Conclusions: The NAFLD CV risk score and MPV accurately predict 1-year risk of MACE thereby allowing better identification of patients that require optimisation of their cardiovascular risk profile.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.